Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DFR
|
|||
| Former ID |
DNCL001607
|
|||
| Drug Name |
FX005
|
|||
| Synonyms |
TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2/3 | [1] | |
| Company |
Flexion Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H7Cl2NO3
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)
|
|||
| InChIKey |
TXEIIPDJKFWEEC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 594839-88-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:78538
|
|||
| ADReCS Drug ID | BADD_D02107 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00791492) An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.